SK Hynix Shares Fall as Workers Reject Wage Deal 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Nvidia Options Price in $280 Billion Earnings Swing 
Tesla Raises Cybertruck Prices by $5,000 in US 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Add as a preferred source on Google
PARSIPPANY, N.J., April 26, 2018 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Thursday, May 3, 2018. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call from Pacira will be Dave Stack, chairman and chief executive officer, and other members of the company’s senior management team.
The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) ten minutes prior to the start of the call and providing the Conference ID 6585169. A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and providing the Conference ID 6585169. The replay of the call will be available for one week from the date of the live call.
The live, listen-only webcast of the conference call can also be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the call.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Investor Contact: Pacira Pharmaceuticals, Inc. Christian Pedetti, (973) 254-4387 [email protected]
